Clinical Trial

Waterdrop Inc. Announces First Quarter 2024 Unaudited Financial Results

BEIJING, June 5, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated…

2 months ago

Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion

The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the “Freedom System”) and SCHOTT Pharma, manufacturer of…

2 months ago

Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion

The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the “Freedom System”) and SCHOTT Pharma, manufacturer of…

2 months ago

Inspire Names Health Tech Leader Brett Kleger as New CEO

ARLINGTON, VA / ACCESSWIRE / June 5, 2024 / Inspire, the world's leading online health community and real-world data platform,…

2 months ago

Avinger Increases Focus on Coronary Development, Reduces Operating Costs of Peripheral Business

REDWOOD CITY, CA / ACCESSWIRE / June 5, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and…

2 months ago

Rett Syndrome Research Trust Launches Roadmap to Cures to Advance Next-Generation Genetic Medicines into Clinical Trials

Roadmap to Cures is an initiative that seeks to raise $40M over the next four years to advance genetic medicine…

2 months ago

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON,…

2 months ago

GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose…

2 months ago

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline…

2 months ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE…

2 months ago